In general, CDK inhibitors are less effective or not at all in p53-intact cells, as DNA damage-induced activation of p53 prevents premature cell-cycle progression, but much more effective in p53-deficient cancer cells at potentiating cytotoxic agents [50]. The gene discussed is TP53; the disease is cancer.